Eli Lilly has some formidable competition coming in the GLP-1 diabetes class, so it’s wasting no time looking for growth avenues for its contender, Trulicity. And if new data are any indication, it may have just found one.Original Article
As diabetes heats up, Lilly looks for Trulicity edge with positive SGLT2 combo data
